As stated before, due to the relation between DLL3 and ASCL1, and since it is frequently upregulated in neuroendocrine subtypes in SCLC, DLL3 has emerged as a promising therapeutic target in this tumor subtype [46]. This evidence concerns the gene DLL3 and neoplasm.